Letrozole Tablet, Film Coated
Product Images NDC 0093-7620

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 0093-7620). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sturctural Formula Of Letrozole (Image 1)

Chemical structure of Letrozole showing the molecular arrangement including aromatic rings and nitrogen-containing groups as depicted.*

FDA Label Image

Figure01 (Image 2)

A survival curve chart comparing Letrozole and Tamoxifen treatments over 72 months. The y-axis represents the survival probability from 0.0 to 1.0, and the x-axis displays time in months from 0 to 72. The chart includes numbers of patients at risk at various time points below the x-axis for both treatments, with Letrozole represented by a solid line and Tamoxifen by a dashed line.*

FDA Label Image

Figure02 (Image 3)

A line chart comparing progression-free survival over 60 months for Letrozole 2.5 mg and Tamoxifen 20 mg. The vertical axis represents progression-free fraction, ranging from 0 to 1.0, and the horizontal axis shows time in months from 0 to 60. Two curves indicate decreasing progression-free survival over time for both drugs, with Letrozole plotted as a solid line and Tamoxifen as a dashed line.*

FDA Label Image

Figure03 (Image 4)

A survival curve graph comparing two treatment groups, labeled "Letrozole 1st" and "Tamoxifen 1st." The x-axis represents time in months from 0 to 60, and the y-axis represents the proportion alive from 0 to 1. The graph shows a decline in survival over time for both groups, with the Letrozole group depicted with a solid line and the Tamoxifen group with a dashed line.*

FDA Label Image

Figure04 (Image 5)

A Kaplan-Meier plot depicting time to progression in days for treatment groups including Letrozole 0.5 mg, Letrozole 2.5 mg, and MA. The y-axis shows the proportion of patients without progression over time, and the x-axis represents time to progression in days, up to 1000 days.*

FDA Label Image

Figure05 (Image 6)

A Kaplan-Meier survival curve chart depicting time to progression in days for three treatment groups: Letrozole 0.5 mg, Letrozole 2.5 mg, and AG. The x-axis represents time to progression in days up to about 1000 days, and the y-axis shows the proportion of patients without progression, ranging from 0 to 1. Each treatment is represented by a different line style.*

FDA Label Image

Image (Image 7)

Letrozole Tablets, USP 2.5 mg film-coated tablets label. The label states each tablet contains 2.5 mg Letrozole, with 30 tablets per package. It includes storage instructions to keep at 20 to 25°C, dispensing information, a warning to keep out of reach of children, and notes that the product contains FD&C Yellow No. 5 (tartrazine) as a color additive. The product is manufactured by Teva Pharmaceuticals USA, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.